Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SORT1 | Q99523 | 2/20 | 0.52 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.44 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.44 |
| ▸ | LSS | P48449 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 4/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | MLYCD | O95822 | 1/20 | 0.43 |
| ▸ | PPARD | Q03181 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17339230 | 0.90 | SORT1 (0.52) | SORT1TRPV1PPARAPPARDPPARG | |
| SCHEMBL17339354 | 0.86 | LMNA (0.59) | SORT1TRPV1LMNAHPGDP2RX1 | |
| SCHEMBL17339497 | 0.84 | TRPV1 (0.49) | TRPV1LMNA | |
| SCHEMBL17339319 | 0.84 | SORT1 (0.51) | SORT1TRPV1LMNAHPGDP2RX1 | |
| SCHEMBL17339394 | 0.83 | PPARA (0.65) | PPARAPPARDPPARG | |
| SCHEMBL28146169 | 0.82 | SORT1 (0.54) | SORT1DDR1LMNAHPGDP2RX1 | |
| SCHEMBL17339539 | 0.82 | SMN1; SMN2 (0.50) | TRPV1LMNAHPGD | |
| SCHEMBL17339455 | 0.81 | TRPV1 (0.66) | TRPV1LSSPPARAMGLLMLYCD | |
| SCHEMBL17339641 | 0.81 | TRPV1 (0.51) | TRPV1LMNAPPARG | |
| SCHEMBL17339525 | 0.81 | PPARA (0.58) | HPGDPPARAPPARDPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190119281-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | LOXO ONCOLOGY INC (US) | 2019-04-25 | — | — | US | disclosed |
| EP-3154978-B1 | PYRAZOLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BRUTON'S TYROSINE KINASE | LOXO ONCOLOGY INC (US) | 2019-04-03 | — | — | EP | disclosed |
| US-9975897-B2 | Pyrazolopyrimidine derivatives useful as inhibitors of Bruton's tyrosine kinase | LOXO ONCOLOGY, INC. (US) | 2018-05-22 | — | — | US | disclosed |
| US-20170129897-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | LOXO ONCOLOGY, INC. | 2017-05-11 | — | — | US | disclosed |
| EP-3154978-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BRUTON'S TYROSINE KINASE | Redx Pharma Plc (GB) | 2017-04-19 | — | — | EP | disclosed |
| WO-2015189620-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF BRUTON'S TYROSINE KINASE | REDX PHARMA PLC (GB) | 2015-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119281-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LCK | SORT1 4760/4885DDR1 2009/4885TRPV1 3141/4885 |
| US-20170129897-A1 | Pyrazolopyrimidine Derivatives Useful as Inhibitors of Bruton's Tyrosine Kinase | BTK, SYK, LCK | SORT1 4760/4885DDR1 2009/4885TRPV1 3141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.